The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.
Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
Open accessAbstract
The farnesoid X receptor (FXR) is a nuclear receptor that plays key roles in hepatoprotection by maintaining the homeostasis of liver metabolism. FXR null mice display strong hepatic inflammation and develop spontaneous liver tumors. In this report, we demonstrate that FXR is a negative modulator of nuclear factor κB (NF-κB)–mediated hepatic inflammation. Activation of FXR by its agonist ligands inhibited the expression of inflammatory mediators in response to NF-κB activation in both HepG2 cells and primary hepatocytes cultured in vitro . In vivo , compared with wild-type controls, FXR−/− mice displayed elevated messenger RNA (mRNA) levels of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interferon-inducible protein 10, and interferon-γ in response to lipopolysaccharide (LPS). Examination of FXR−/− livers showed massive necroses and inflammation after treatment with LPS at a dose that does not induce significant liver damage or inflammation in wild-type mice. Moreover, transfection of a constitutively active FXR expression construct repressed the iNOS, COX-2, interferon-inducible protein 10 and interferon-γ mRNA levels induced by LPS administration. FXR activation had no negative effects on NF-κB-activated antiapoptotic genes, suggesting that FXR selectively inhibits the NF-κB-mediated hepatic inflammatory response but maintains or even enhances the cell survival response. On the other hand, NF-κB activation suppressed FXR-mediated gene expression both in vitro and in vivo , indicating a negative crosstalk between the FXR and NF-κB signaling pathways. Our findings reveal that FXR is a negative mediator of hepatic inflammation, which may contribute to the critical roles of FXR in hepatoprotection and suppression of hepatocarcinogenesis. (Hepatology 2008;48:1632–1643.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“FXR agonists are known to alleviate endoplasmic reticulum stress and suppress oxidative damage by upregulating antioxidant and anti-apoptotic pathways [42, 43].”
From High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics. (2026) · cites this paper as [43]
Experimental — accuracy not yet measuredIn the citing paper
“Ablation of Nr1h4 (hereafter referred to as Fxr) not only promotes cholestasis but also NAFLD, NASH and HCC in mice (Kim et al., 2007; Lu et al., 2000; Wang et al., 2008; Watanabe et al., 2004; Yang et al., 2007).”
From Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis (2016) · cites this paper as Wang et al., 2008
In the citing paper
“Next to their extensive effect on cell metabolism, they are able to mediate anti-inflammatory effects through direct interaction with other transcription factors, such as NF-κB or activator protein-1 (AP-1) [26,27], and even repress proinflammatory gene expression by interfering with TLR signaling.[28]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [27]
In the citing paper
“In brief, FXR interacts with NF-κB signaling and inhibits pro-inflammatory genes (e.g., TNF-α, inducible nitric oxide synthase (iNOS), Cyclooxygeanse-2 (COX-2), CCL-2 and IL-1β)), while NF-κB activation reciprocally antagonizes FXR activity.[27,52,53]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [27]
In the citing paper
“Additionally, FXR -/-mice were more susceptible to inflammatory stress, highlighting the anti- inflammatory properties of FXR.[27]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature reviews. Immunology · doi:10.1038/nri1703 · Cited by 3,175
Wang, C.-Y., Mayo, M., Korneluk, R., Goeddel, D., & Baldwin, A. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,950
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben‐Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,423
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Self-citationAggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,586
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2005) · Nature · doi:10.1038/nature03988 · Cited by 1,287
Flagged first, then by citations
3 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–577 of 577
The Role of Bile Acid Receptors in Chronic Inflammatory Diseases
Park, R., & Ji, J. D. (2017) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2017.24.5.253 · Cited by 4
“DNA-binding by the transcription factor, similar to the mechanism of other nuclear receptors [36].”
BackgroundBrea, Á., Pintó, X., Ascaso, J. F., Blasco, M., Díaz, Á., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Millán, J., & Pedro‐Botet, J. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.001 · Cited by 6
Ceulemans, L. J., Canovai, E., Verbeke, L., Pirenne, J., & Farré, R. (2016) · Acta chirurgica Belgica · doi:10.1080/00015458.2016.1215953 · Cited by 4
“[4,24] From a mechanistical point of view, several studies revealed a close interaction between FXR and the NF-jB pathway.[4,25,27,31] Interestingly, intestinal inflammation (by TNF-a and IL-1b) strongly reduces FXR activation, probably via NFjB dependent tethering of FXR.”
BackgroundImpact of Nuclear Receptors CAR, PXR, FXR, and VDR, and Their Ligands On Enzymes and Transporters
Tirona, R. G. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0840-7_4 · Cited by 3
Zhang, H.-L., Wang, Z.-X., Zhao, Y.-Q., Deng, X.-Y., Zhang, J., Shang, F., Zhang, H.-J., Liu, Y., Wang, H.-B., Yang, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70112-z · Cited by 3
Self-citationEffects of bile acids and gut microbiota interactions on neurological and psychiatric disorders
Pei, X., Wang, X., Lu, H., Wu, J., Xu, L., Chen, X., Deng, L., & Xu, H. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102069 · Cited by 3
Zhang, J., Jiang, D., Zhang, X., Yang, Y., & Wu, Z. (2026) · Food Research International · doi:10.1016/j.foodres.2026.118797 · Cited by 2
Alsharif, O., & Rombouts, K. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00037-9 · Cited by 3
Zhang, Y., Liu, L., Song, R., Qu, Z., Wang, T., Liang, L., Wang, S., Zhang, S., Li, H., & Wang, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1653372 · Cited by 1
Yu, X., Zhang, Y., Wu, B., Zhao, B., & Wang, C. (2025) · Drug metabolism reviews (Softcover ed.) · doi:10.1080/03602532.2025.2558654 · Cited by 3
“…hepatic adipogenesis and lipid production and accelerating lipoprotein clearance in the blood (lambert et al. 2003). in addition to inflammatory diseases (Kim, Xiao, et al. 2015), FXR activation also inhibits the target genes of NF-κB, exerting anti-inflammatory effects (wang et al. 2008).”
Han, M., Cheng, Y., Wang, W., Ye, S., Kong, L., Zhang, Y., & Zhang, H. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117200 · Cited by 3
Fang, H., Wang, X.-X., Wang, Z.-Y., Ma, X., Zhang, L.-Y., & Yang, L. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106870 · Cited by 3
Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study
Mooranian, A., Chester, J., Johnston, E., Ionescu, C. M., Walker, D. P., Jones, M., Wagle, S. R., Kovačević, B., Foster, T., Mikov, M., et al. (2022) · Biomolecules · doi:10.3390/biom12070877 · Cited by 3
Jamshidi, V., Hashemi, S., Khalili, A., Fallah, P., Ahmadian-Attari, M., Beikzadeh, L., Mazloom, R., Najafizadeh, P., & Bayat, G. (2021) · Avicenna Journal of Phytomedicine · doi:10.22038/ajp.2021.18227 · Cited by 3
“Increased mRNA level of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), in FXR- deficient mice is an important indicator of the protective role of hepatic FXR against inflammatory reactions (Wang et al., 2008).”
BackgroundInfluentialBile Acids as Signaling Molecules
Claudel, T., & Trauner, M. A. (2020) · Liver · doi:10.1002/9781119436812.ch25 · Cited by 6
Neumann, S., Peyroux, E. M., Woodall, M. J., Shields, N. J., Young, S. L., & Pattison, S. T. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88137 · Cited by 4
Developments in understanding bile acid metabolism
Morimoto, K., Itoh, H., & 渡辺, 光. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.75 · Cited by 3
Farnesoid X receptor expression is reduced in human hepatocellular carcinoma
Zhang, W.-Y., Chen, P., Zhao, Y.-Y., & Gui-yu, L. (2012) · 中国人民解放军军医大学学报：英文版 · doi:10.1016/s1000-1948(12)60001-x · Cited by 3
Rizzo, G., Passeri, D., Franco, F. D., Ciaccioli, G., Sadeghpour, B., Pellicciari, R., Pruzanski, M., & Adorini, L. (2010) · doi:10.1016/s0168-8278(10)61115-4 · Cited by 3
“INT-747 also shows anti-fibrotic (Fiorucci et al., 2004; Wang et al., 2009) and anti-inflammatory (Wang et al., 2008) properties, and modulates lipid (Rizzo et al., 2006) and glucose (Cipriani et al., 2009) metabolism.”
BackgroundJia, Y., Li, Q., Xu, X., Kong, X., Sun, G., Zhang, Z., Zhang, Y., Li, L., He, W., Liu, X., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117009 · Cited by 2
The interplay between the microbiome and immune cells in metabolic homeostasis and disease
Shapiro, H., Jickeli, B., Niv, I., Ernan, B., & Elinav, E. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.06.004 · Cited by 2
Du, M., Ye, L., Wang, C., Jiang, T., & Liu, F. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107194 · Cited by 2
Dean, A. E., Guzior, D. V., Quinn, R. A., Gaulke, C. A., & Anakk, S. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100954 · Cited by 2
“However, Bifidobacterium , known to deconjugate bile acids was higher, and some of its species are linked to HCC (21, 38, 50).”
Teng, F., Liu, H., Jiang, Y., Xu, S., Wang, X.-J., Wang, X., Yang, Z., Li, M., Wang, R.-F., Wang, Z.-T., et al. (2025) · Phytotherapy Research · doi:10.1002/ptr.70049 · Cited by 2
DMF, an activator of Nrf2, could mitigate cholic-acid-induced liver damage in high-fat diet
Abu-Halaka, D., Rauchbach, E., Zeigerman, H., & Tirosh, O. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100581 · Cited by 2
The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis
Ashraf, T., Abunada, O., Seerani, N., Ali, K., Muhammad, A., Mir, S. L., Shah, S. A. M., Hassaan, M., Kumar, V., Abbas, W., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03812-3 · Cited by 2
“With its unique mechanism of action and potentially favorable safety profile, Seladelpar presents an opportunity to address the limitations of previous treatments and improve outcomes for individuals with PBC [19].”
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Sohal, A., & Kowdley, K. V. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2330738 · Cited by 3
“It has been suggested that OCA exerts its anti-inflammatory and antifibrotic properties by mediating nuclear factor-kB [42].”
BackgroundShahrulnizam, N. A. N. M., Goon, M. D. M. E., Rahim, S. A., Lew, S. W., Kadir, S. H. S. A., & Ibrahim, E. (2024) · Genes & Nutrition · doi:10.1186/s12263-024-00742-9 · Cited by 2
Identification and validation of immune related core transcription factors GTF2I in NAFLD
Zhang, M., Zhang, Y., Jiao, X., Lai, L., Qian, Y., Sun, B., & Yang, W. (2022) · PeerJ · doi:10.7717/peerj.13735 · Cited by 2
Everaert, B., Laere, S. V., Lembrechts, R., Hoymans, V. Y., Timmermans, J., & Vrints, C. J. (2019) · Stem Cells International · doi:10.1155/2019/9545261 · Cited by 4
“Activation of FXR pathways in mouse models of atherosclerosis could almost completely inhibit aortic atherosclerotic lesion formation [32], attenuated the proinflammatory expression of IL1ß, IL6 and TNF [33] and negatively modulated NFκB-mediated inflammation [34].”
BackgroundGut Microbiome and Liver Cancer
McVey, J. C., Zhang, Q., Greten, T. F., & Ma, C. (2021) · Physiology in health and disease · doi:10.1007/978-3-030-67951-4_7
Steiner, C. A., & Higgins, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_23 · Cited by 4
Bowlus, C. L., Nevens, F., Kowdley, K. V., Bonder, A., Capozza, T. A., Li, J., Nair, R., Trauner, M. A., & Jones, D. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70832 · Cited by 1
Bile acids in cancer: From metabolism to immunomodulation
Fang, Q., & Schneider, K. M. (2026) · Immunity · doi:10.1016/j.immuni.2026.07.003 · Cited by 2
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 5
Xu, J., Lv, K., Wang, S., Luo, G., Chen, S., Guo, N., Li, Y., & Li, G. (2026) · Small · doi:10.1002/smll.202512173 · Cited by 1
Youssef, E., Mansour, A., & El-sherbiny, I. M. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107653
Bile acids for metabolic dysfunction-associated steatotic liver disease in adults
Ashmawy, R. E., Blyuss, O. B., Nikolova, D., Pavlov, C. S., Gluud, C. N., & Andrenacci, P. J. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014850
Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )
Glatthar, R., & Arch, R. H. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc274 · Cited by 1
Ameliorative effect of animal bile preparations on dextran sulfate sodium‐induced colitis in mice
Watanabe, S., Fujita, K., Nishida, T., & Imura, J. (2018) · doi:10.1002/tkm2.1094 · Cited by 1
“Details of the measurement of the expression of interleukin (IL)-1β and IL-6 mRNA in the colon tissues have been reported previously [12].”
MethodNuclear Receptor Regulation of the Adaptive Response of Bile Acid Transporters in Cholestasis
Wagner, M., Zollner, G., & Trauner, M. A. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1253225 · Cited by 103
Bile Acids and Bilirubin in Liver Immunology
Zhu, C., Claudel, T., & Trauner, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_7
Wang, T., Wang, J., Huangfu, B., He, X., & Huang, K. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6c01607
Ajugol Improves Liver Fibrosis by Modulating Bile Acid and Arachidonic Acid Metabolism in Mice.
Wei, X., Wang, F.-Y., Zhang, D.-Q., Zhang, L.-H., Xu, F.-P., Chen, G.-F., Zhang, H., Liu, P., Liu, W., & Xu, Y. (2026) · Phytotherapy Research · doi:10.1002/ptr.70488
Sun, L., Chen, H., Fan, W. J., Shi, Z. Y., Zhao, Y., Wang, Y., & Nie, Y. (2026) · Journal of Digestive Diseases · doi:10.1111/1751-2980.70072
Self-citationKowalska-Ciszek, E., Zelkowska, J., Jańczyk, W., Patla, K., Siejka, A., Klimiuk-Balas, J., Zielińska, M., Świąder-Leśniak, A., Godzień, J., Cysewski, D., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198742
Cai, Z., Wen, X., Wu, H., & Luo, Y. (2026) · Clinical & Translational Metabolism · doi:10.1007/s12018-026-09337-x
Spatial immune niche remodeling of the neutrophil-macrophage axis inchronic liver disease
Ding, J., Xiong, X., Zhang, C., Fang, H., & Li, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1902627
“More and more mouse knockout and cell clearance experiments have shown that FXR agonists can dynamically regulate bile acid metabolism and directly block the upstream NF-κ B inflammatory pathway in macrophages in vivo (Wang et al., 2008).”
Mu, K., He, M., Liao, R., Shao, C., Xie, P., Xie, J., Liu, Y., Ju, Z., Zhong, K., Yuan, Y., et al. (2026) · Nutrients · doi:10.3390/nu18162641
Wang, X., Jiang, Y., Feng, L., Luo, Y., Zhang, J., Wang, X., Wang, Y., Ma, Y., Hua, M., Jin, L., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158730
Self-citationQiu, S., Qiang, S., Wang, Z.-B., Yang, L.-H., Guo, S.-F., Zeng, J., Cai, Y., Lai, Z., Xie, D.-D., Che, L., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122201
Development of pH-tunable PLGA nanoparticles for targeted liver delivery of obeticholic acid
Iefremenko, D., Holas, O., Mrozkova, N., Maslova, P., Lochman, L., Pávková, I., Smékalová, M., Loskot, J., Boltnarova, B., & Pávek, P. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108669
Shi, J., Ma, C.-Y., Zhang, X.-H., Liu, K., Liu, J.-Y., Wang, Q.-G., Wang, X.-Q., Cheng, F.-F., & Xu, T. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i17.116590
Cheng, J. (2026) · Hepatology Research · doi:10.1111/hepr.70184
“Preclinical evidence suggests that FXR suppression can relieve inhibition on NF‐κB, thereby amplifying TLR‐driven pro‐inflammatory cytokine production [34].”
Nuclear receptors in age-related diseases: From mechanisms to drug discovery
Zhang, L., Li, X., Ren, C., Hao, Y., Deng, Y., Pan, H., Kim, Y.-B., Fan, S., Huang, C., Ge, G., et al. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103125 · Cited by 1
Razori, M., Hillotte, G. L., Martín, P. L., Barosso, I., Basiglio, C., Ruiz, M. L., & Roma, M. G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111393
“This establishes a vicious cycle that reinforces the inflammatory effects of LPS, since FXR downregulation impairs FXR-induced repression of nuclear factor kappa B (NF-κ B), a transcription factor that is activated by LPS to trigger cytokine release [12].”
Li, W.-B., Zhang, X.-L., Yang, Y.-T., Zhou, Z.-H., Huang, Z., & Li, H. (2025) · International Journal of Clinical Medicine and Pharmacology · doi:10.70731/msky1591
“Wang et al. observed HepG2 cells could show immune responses to LPS in vitro, and liver would be damaged by upregulating immune-related genes such as iNOS, COS-2, CD14 and others [20] .”
Potential Role of Bile Acids in the Pathogenesis and Treatment of PBC
Lu, Y., Wang, D., & Song, L. (2025) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2025.07(02).19
“In addition, downregulation of FXR expression or impaired function results in bile acids promoting inflammatory responses via TGR5 or other receptors [31].”
Fattahi, A. S., Khalili, A., Hashemi, S., Najafizadeh, P., Mazloom, R., Khodayar, S., & Bayat, G. (2024) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2024.2364192
“…and progression of nonalcoholic steatohepatitis (armstrong et al. 2017). it seems that FXR plays an anti-inflammatory role during liver dysfunction (Wang et al. 2008; Zhang et al. 2009) and its activation could prevent liver fibrosis via induction of some anti-fibrotic genes in hepatic stellate…”
Farnesoid X receptor in chronic liver diseases: an immunohistochemical study
Sweed, D., Holah, N. S., Karman, E., Asaad, N. Y., & Mahmoud, S. (2023) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2023.2242920
Awoniyi, M., Wang, J., Ngo, B., Meadows, V., Tam, J. W., Viswanathan, A., Lai, Y., Montgomery, S. A., Farmer, M., Kummen, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.31.466701 · Cited by 2
Endoplasmic reticulum stress in intestinal inflammation: implications of bile acids
Eugene, S. P., & Trinath, J. (2021) · Proceedings of the Indian National Science Academy · doi:10.1007/s43538-021-00031-8
Mice Lacking FXR Are Susceptible to Liver Ischemia-Reperfusion InjuryPreprint
Li, Y., Xu, R., Rao, P., Gomes, C., Moran, E. R., Puchowicz, M., Chang, E. B., Yin, D., & Pierre, J. F. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/739839
ABC Transporters Involved in Cholestasis
Cuperus, F. J. C., Gautherot, J., Halilbasic, E., Claudel, T., & Trauner, M. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679430.ch6
Nouvelles propriétés hépatiques des récepteurs nucléaires FXR et Rev-Erb Alpha
Porez, G. (2014) · theses.fr (ABES) · doi:10.70675/f928fa30z1b88z4999zb8d4zaf18c6efecef
Neue Aspekte zur Pathogenese der NASH
Stremmel, W., Pathil‐Warth, A., & Chamulitrat, W. (2010) · Die Gastroenterologie · doi:10.1007/s11377-009-0373-4
Li, Q., Yu, W.-F., Qiu, B., Zhang, J.-M., & Fei, G.-X. (2010) · doi:10.3724/sp.j.1008.2009.01240
Pharmacological Options for NASH
Stern, C., & Ratziu, V. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_17
Un estudio controlado contra placebo sobre el uso de bezafibrato en colangitis biliar primaria
Ignacio Bezama, F., Sebastián González, V., Nicolás Zañartu, A., Andrés Soffia, P., Pauline Böhm, G., P., L. D., & Francisco Barrera, M. (2020) · Revista Gastroenterología Latinoamericana · doi:10.46613/gastrolat202001-10
Role of bile acid receptors in the regulation of cardiovascular diseases
Shiozaki, Y., Keenan, A. L., & Miyazaki, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00020-8
Schumacher, J. D. (2018) · doi:10.7282/t3-4rpt-6g19
“Treatment of mice with FXR agonists reduced the induction of inflammatory mediators by LPS challenge.(132) Similarly, preventing FXR activity or SUMOylation increases inflammatory mediator expression.”
BackgroundKitamura, T., & Watanabe, S. (2017) · Springer eBooks · doi:10.1007/978-4-431-56062-3_10
Bidirectional interaction between farnesoid X Receptor and MicroRNAs
Krattinger, R. (2016) · doi:10.5167/uzh-134909
Bile Acid Receptors and Liver Regeneration
Fan, M., Ding, L., & Huang, W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420128-6.00009-9 · Cited by 1
Self-citationIntestinal Failure and Parenteral Omega-3 Fatty Acid Lipid Emulsions
Turner, J. M., & Wales, P. W. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8503-2_61-1
Primary Sclerosing Cholangitis (PSC)
Hofer, H., Halilbasic, E., Staufer, K., & Trauner, M. (2013) · Springer eBooks · doi:10.1007/978-3-319-02096-9_20
Metadata
- Authors
- Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W.
- Affiliations
- City Of Hope National Medical Center (US)
- Corresponding author
- Huang, Wendong
- Venue
- Hepatology
- Published
- 2008-11
- Volume
- 48
- Issue
- 5
- Pages
- 1632-1643
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC3056574
- OpenAlex
- W2021998283
- Cited by
- 639
- References
- 52
- Citations by year
- 2026: 30 · 2025: 46 · 2024: 44 · 2023: 46 · 2022: 51 · 2021: 54 · 2020: 45 · 2019: 42 · 2018: 31 · 2017: 42 · 2016: 38 · 2015: 29 · 2014: 31 · 2013: 27 · 2012: 27
- FWCI
- 9.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Sidney Kimmel Foundation for Cancer Research
- Sidney Kimmel Foundation
- National Cancer Institute (P30CA033572)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- farnesoid X receptor, nuclear factor-kappaB, liver inflammation, hepatoprotection, lipopolysaccharide, inducible nitric oxide synthase, cyclooxygenase-2, CXCL10, interferon-gamma, liver necrosis, hepatocarcinogenesis, anti-apoptotic genes
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Cell Line, DNA-Binding Proteins, Homeostasis, Humans, Inflammation, Kidney, Liver, Liver Neoplasms, Necrosis, RNA, Messenger, Transcription Factors, Tumor Necrosis Factor-alpha, NF-kappa B, Receptors, Cytoplasmic and Nuclear, Hepatoblastoma, Mice, Knockout, Cell Line, Tumor, Mice, Cyclooxygenase 2, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
